July 24, 2026

ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical ques...

The ASCO Post

July 24, 2026

ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical ques...

The ASCO Post

July 23, 2026

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

The ROS1 selective inhibitor was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhi...

The ASCO Post

July 23, 2026

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

The ROS1 selective inhibitor was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhi...

The ASCO Post

July 21, 2026

Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types

Diagnosis of a cancer upon emergency department presentation was associated with an elevated mortality rate, which was consistent across 16 analyzed cancer types, according to new research findings pu...

The ASCO Post

July 20, 2026

Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma

Oral nicotinamide may provide a cost-effective strategy for preventing keratinocyte carcinoma (KC) in persons at high risk, according to a study published in JAMA Dermatology. Led by David Perez, BA, ...

The ASCO Post

July 17, 2026

Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors

In a meta-analysis published in The Oncologist, researchers found that second-generation Bruton's tyrosine kinase (BTK) inhibitors had a better cardiovascular safety profile than the first-generation ...

The ASCO Post

July 16, 2026

ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment

A randomized phase III clinical trial by the ECOG-ACRIN Cancer Research Group, published in The New England Journal of Medicine, reported that for patients with newly diagnosed multiple myeloma not un...

The ASCO Post

July 16, 2026

ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment

A randomized phase III clinical trial by the ECOG-ACRIN Cancer Research Group, published in The New England Journal of Medicine, reported that for patients with newly diagnosed multiple myeloma not un...

The ASCO Post

July 15, 2026

Tafasitamab/Lenalidomide Combination vs R-CHOP in High-Risk DLBCL: Phase III frontMIND Trial

In patients newly diagnosed with high-risk large B-cell lymphoma, the addition of the CD19 monoclonal antibody tafasitamab plus the immunomodulatory drug lenalidomide (Tafa/Len) to standard therapy le...

The ASCO Post